New Risk • Jun 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€2.22m market cap, or US$2.58m). Minor Risk Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Board Change • May 20
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Hongming Luo is the most experienced director on the board, commencing their role in 2025. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Tillkännagivande • Feb 14
Republic Technologies Inc. announced that it expects to receive CAD 4.08523 million in funding Republic Technologies Inc. announced a non-brokered private placement offering of up to 14,087,000 special warrants at an issue price of CAD 0.29 for the proceeds of CAD 4,085,230 on February 13, 2026. Each Special Warrant will automatically convert, for no additional consideration, into one common share in the capital of the Company. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. Securities issued under the Offering will be subject to a four-month hold period from the date of closing of the Offering. Tillkännagivande • Feb 07
Republic Technologies Inc. Appoints Xinbo Zhu as Special Advisor to the Board and Member of Infrastructure and Energy Advisory Committee Republic Technologies Inc. announced the appointment of Xinbo Zhu as Special Advisor to the Board and member of the newly formed Infrastructure and Energy Advisory Committee (IEAC). Mr. Zhu currently serves as Senior Vice President and Chief Financial Officer of Canadian Solar Inc., a global renewable energy company with operations spanning manufacturing, project development, and asset ownership across multiple continents. Over more than two decades, he has held senior executive roles overseeing finance, risk, supply chain, and investment decision-making in complex, capital-intensive environments. Mr. Zhu holds an MBA from the Rotman School of Management at the University of Toronto and a Master of Engineering in Electronic Engineering from Shanghai Jiao Tong University. His career spans senior leadership roles in public companies and multinational organizations across North America and Asia, with a consistent focus on disciplined capital allocation and risk-adjusted growth. The Company will leverage Mr. Zhu’s expertise to help guide its efforts in creating scalable, Ethereum backed, digital infrastructure. His experience will offer valuable advice in the Company’s decision-making efforts as it executes on its business plan and evaluates future growth opportunities. Tillkännagivande • Oct 21
Republic Technologies Inc. announced that it expects to receive CAD 126.432 million in funding Republic Technologies Inc. announced that it has entered into a financing agreement with an institutional investor to issue secured convertible notes in the principal amount of CAD 140,480,000 at discount of 10% and warrants for gross proceeds of CAD 126,432,000 on October 20, 2025. The company will issue convertible notes for gross proceeds of CAD 14,048,000 in its initial tranche. The convertible note will bear 0% interest and have term of 24 months. The notes will be convertible into common shares. In connection with the first drawdown, the company proposes to issue to the investor up to 28,000,000 common share purchase warrants, exercisable to purchase common shares at a price of CAD 0.50 per common share for a period of 5 years from the date of issuance. The closing of the first drawdown is expected to occur on or about October 24, 2025 and will be subject to customary conditions. The first drawdown convertible note, warrants and any common shares issuable upon conversion of the note or exercise of warrants will be subject to a statutory hold period of four months plus one day in accordance with applicable Canadian securities laws. The company may pay customary finder's fees in connection with the proposed financing, subject to CSE policies. No insiders of the company are expected to participate in the proposed financing. Tillkännagivande • Jun 23
Beyond Medical Technologies Inc. announced that it has received CAD 2.09875 million in funding On June 23, 2025, Beyond Medical Technologies Inc. closed the transaction. The company announced that it has issued CAD 418,750in second and final tranche. The Notes are convertible into common shares of the Company at the option of the holder at a conversion price of CAD 0.53 per share. The Notes have a 12-month term and do not bear interest. All securities issued under the Financing are subject to a statutory hold period in accordance with applicable securities laws. The company has raised CAD 2,098,750 in the transaction. Tillkännagivande • May 13
Beyond Medical Technologies Inc., Annual General Meeting, Jul 09, 2025 Beyond Medical Technologies Inc., Annual General Meeting, Jul 09, 2025. Location: british columbia, vancouver Canada Tillkännagivande • May 07
Beyond Medical Technologies Inc. announced that it expects to receive CAD 2.5 million in funding Beyond Medical Technologies Inc. announced a non-brokered private placement that it will issue senior secured non-interest bearing convertible notes in the aggregate principal amount of CAD 1,600,000 which principal amount will be convertible into common shares of the Company at the option of the holder at a conversion price of CAD 0.41 and senior secured non-interest bearing convertible notes in the aggregate principal amount of CAD 900,000, which principal amount will be convertible into common shares of the Company at the option of the holder at a conversion price of the lesser of CAD 0.53 for the aggregate gross proceeds of up to CAD 2,500,000 on May 6, 2025. The Notes will be issued with a term of 12 months. In the event the Non-Interest Bearing Notes are not converted by the holder during the term, the Company will pay a 24% premium on the principal outstanding. The Discounted Conversion Notes will automatically convert into common shares of the Company in the event the 10-day volume weighted average price of the common shares exceeds CAD 1.06. In the event the Discounted Conversion Notes are not converted by the holder during the term, the Company will pay a 15% premium on the principal outstanding. All securities issued under the Financing will be subject to a statutory hold period in accordance with applicable securities laws. Tillkännagivande • Apr 15
Beyond Medical Technologies Inc. announced that it has received CAD 0.979657 million in funding On April 14, 2025. Beyond Medical Technologies Inc. closed the transaction and issued 8,987,677 units at a price of CAD 0.109 per unit for gross proceeds of CAD 979,656.793. Each unit comprising one common share in the capital of the company. The securities are subject to a statutory hold period of four months and one day from the date of issuance. Tianrui Zhang holding more than 10% of the company's outstanding shares, acquired or exercised control over a total of 1,100,000 units under the private placement. Immediately before completion of the private placement, Zhang beneficially owned and controlled 2,967,800 common shares and 1,467,800 common share purchase warrants, representing 12.73% of the company's issued and outstanding common shares on a non-diluted and 17.90% on a partially diluted basis, assuming exercise of his warrants. Immediately after completion of the private placement, Zhang beneficially owned and controlled a total of 4,067,800 common shares and 1,467,800 common share purchase warrants, representing 12.59% of the company's issued and outstanding common shares on a non-diluted basis and 16.39% on a partially diluted basis, assuming exercise of his warrants. Tillkännagivande • Apr 02
Beyond Medical Technologies Inc. announced that it expects to receive CAD 1.1726 million in funding Beyond Medical Technologies Inc. announced a non-brokered private placement of up to 9,020,000 common shares at a price of CAD 0.13 per share for the gross proceeds of up to CAD 1,172,600 on April 1, 2025. The securities will be subject to a statutory hold period of four months and one day from the date of issuance. The offering remains subject to approval by the Canadian Securities Exchange (CSE). The Company may pay finder's fees to eligible finders in connection with the offering, subject to compliance with applicable securities laws and CSE policies. Tillkännagivande • Feb 27
Beyond Medical Technologies Inc. (OTCPK:DOCK.F) entered into a non-binding letter of intent to acquire Elite Horizon Management, Inc. for CAD 1.13 million. Beyond Medical Technologies Inc. (OTCPK:DOCK.F) entered into a non-binding letter of intent to acquire Elite Horizon Management, Inc. for CAD 1.13 million on February 26, 2025. The consideration consists of 11.25 million shares of Beyond Medical Technologies Inc. to be issued for common equity of Elite Horizon Management, Inc. Completion of the Proposed Transaction will be subject to a number of conditions precedent, including, but not limited to: (i) satisfactory completion of due diligence investigations by each of the Company and Horizon; (ii) the negotiation and execution of a definitive agreement which will contain terms and conditions customary for transactions of this nature (the "Definitive Agreement") on or before March 31, 2025; and (iii) receipt of all requisite regulatory and third party approvals, including the approval of the Canadian Securities Exchange. Tillkännagivande • Feb 13
Beyond Medical Technologies Inc. announced that it expects to receive CAD 0.375 million in funding Beyond Medical Technologies Inc. announced a non-brokered private placement that it will issue up to 7,500,000 units of the company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 375,000 on February 11, 2025. Each Unit will consist of one common share in the capital of the Company and one common share purchase warrant. Each Warrant will entitle the holder thereof to purchase one Share at a price of $0.075 per Share for a period of 24 months from the date of issuance. The securities offered pursuant to the Offering will be subject to a statutory hold period of four months and a day from the date of issuance. Finder's fees may be payable in connection with the Offering, all in accordance with the policies of the Canadian Securities Exchange. Tillkännagivande • Feb 06
Beyond Medical Technologies Inc Announces CEO Changes Beyond Medical Technologies Inc. announced that it has appointed Daniel Liu as Chief Executive Officer of the Company. Mr. Liu replaces Kal Malhi in these roles, following Mr. Malhi's resignation as Chief Executive Officer and as a director, effective January 30, 2025. Mr. Malhi leaves Beyond Medical to pursue other ventures but will remain available to consult for the Company as required. The Company would like to thank Mr. Malhi for his service and wishes him the best in his future endeavors. Tillkännagivande • Feb 05
Beyond Medical Technologies Inc. Announces Board Changes Beyond Medical Technologies Inc. announced that it has appointed Daniel Liu as a director of the Company. Mr. Liu replaces Kal Malhi in these roles, following Mr. Malhi's resignation as Chief Executive Officer and as a director, effective January 30, 2025. Mr. Malhi leaves Beyond Medical to pursue other ventures but will remain available to consult for the Company as required. The Company would like to thank Mr. Malhi for his service and wishes him the best in his future endeavors. Tillkännagivande • May 08
Beyond Medical Technologies Inc., Annual General Meeting, Jul 10, 2024 Beyond Medical Technologies Inc., Annual General Meeting, Jul 10, 2024. Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Michael Kelly was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Nov 30
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$79k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$667k free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Negative equity (-CA$79k). Revenue is less than US$1m. Market cap is less than US$10m (€290.1k market cap, or US$316.6k). Reported Earnings • Nov 26
Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.004 loss in 3Q 2021) Third quarter 2022 results: CA$0.004 loss per share (in line with 3Q 2021). Revenue: CA$21.9k (down 92% from 3Q 2021). Net loss: CA$356.2k (loss widened 17% from 3Q 2021). Reported Earnings • Sep 01
Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.005 loss in 2Q 2021) Second quarter 2022 results: CA$0.003 loss per share (up from CA$0.005 loss in 2Q 2021). Revenue: CA$35.4k (down 87% from 2Q 2021). Net loss: CA$225.6k (loss narrowed 43% from 2Q 2021). 
